ຊອກຫາ (ຂ່າວ)

Innovent Dosed First Participant In Phase 3 Clinical Study Of IBI354 (Novel HER2 ADC) For First Line Treatment Of HER2-Positive Breast Cancer

health top

(MENAFN - PR Newswire)SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, ...
2026-02-12 19:16:07